Eli Lilly and Company has completed acquisition of two biopharmaceutical companies – Versanis Bio and Sigilon Therapeutics - and their lead assets focused on obesity and diabetes.
Lilly announced. -Today at 06:31 pm- MarketScreener
ENHERTU® has demonstrated clinically meaningful progression-free survival and overall survival in topline results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial.
The.